Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of izokibep in moderate to severe hidradenitis suppurativa
jRCT2031230501Phase 3Completed
- Sponsor
- Acelyrin
- Start
- Mar 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Placebo then izokibep with Izokibep (2 arms). Primary endpoint: HiSCR75 at Week 16. Started Mar 2024; status: completed.
02
Drugs
izokibep
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2031230501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230501.